Hematologic Abnormalities in Treatment-Naïve HIV patients
Date
2010
Authors
Akinbami, A.
Oshinaike, O.
Adeyemo, T.
Adediran, A.
Dosumu, O.
Dada, M.
Durojaiye, I.
Adebola, A.
Osunkalu, V.
Journal Title
Journal ISSN
Volume Title
Publisher
Infectious Disease: Research and Treatment
Abstract
Objectives: Hematologic abnormalities, indicated by a deranged full blood count, are common manifestations and important prognostic tools for human immunodeficiency virus (HIV) infection and AIDS. This study aimed to determine the prevalence of cytopenia and its relationship to the degree of immunosupression in HIV treatment-naïve patients. Methods: This was a cross-sectional study of treatment-naïve HIV-infected clients who enrolled at the HIV clinic of Lagos State
University Teaching Hospital (LASUTH) between December 2009 and June 2010. Participants had samples taken for full blood count and CD4 counts, which are free routine pre-requisite and pre-treatment evaluations done for all registered HIV patients at LASUTH. They were asked to fill the structured questionnaires to obtain demographic data, with assistance if necessary. Results: A total of 205 cases were reviewed: 24.2% had anemia (PCV , 30%), 26.8% had leucopenia (white blood cell ,4,000/L) and 16.1% had thrombocytopenia (platelet count ,150,000/L) at enrollment. The degree of cytopenia was directly related to the degree of immunosupression. Conclusion: About one-fifth of HIV treatment-naïve patients were cytopenic at enrollment and the degree of cytopenia was directly related to the degree of immunosupression. It is necessary to investigate various causes of cytopenia in these patients so as to administer a specific intervention.
Description
Staff Publications
Keywords
HIV , hematological abnormalities , Nigeria , AIDS , cytopenia , Research Subject Categories::MEDICINE
Citation
Akinsegun, A., Oshinaike, O., Adeyemo, T., Adediran, A., Dosumu,O., Dada, M., Durojaiye, I., Adebola, A., Osunkalu, V. (2010). Hematologic Abnormalities in Treatment-Naïve HIV patients. Infectious Disease: Research and Treatment, 3:45-49.